These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31364470)

  • 21. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
    Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
    Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case-control study to evaluate efficacy of screening for faecal occult blood.
    Lazovich D; Weiss NS; Stevens NG; White E; McKnight B; Wagner EH
    J Med Screen; 1995; 2(2):84-9. PubMed ID: 7497161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme.
    Mlakar DN; Bric TK; Škrjanec AL; Krajc M
    Radiol Oncol; 2018 Jul; 52(4):413-421. PubMed ID: 30511936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme.
    Fraser CG; Digby J; McDonald PJ; Strachan JA; Carey FA; Steele RJ
    J Med Screen; 2012 Mar; 19(1):8-13. PubMed ID: 22156144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma.
    Tibble J; Sigthorsson G; Foster R; Sherwood R; Fagerhol M; Bjarnason I
    Gut; 2001 Sep; 49(3):402-8. PubMed ID: 11511563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study.
    Hoepffner N; Shastri YM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J
    Aliment Pharmacol Ther; 2006 Jan; 23(1):145-54. PubMed ID: 16393292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Improvement in screening for colorectal cancer associated with the use of immunochemical faecal occult blood test].
    Launoy G
    Pathol Biol (Paris); 2009 Sep; 57(6):488-92. PubMed ID: 18834677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples.
    Guittet L; Bouvier V; Mariotte N; Vallee JP; Levillain R; Tichet J; Launoy G
    Int J Cancer; 2009 Sep; 125(5):1127-33. PubMed ID: 19431212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should organised faecal occult blood test screening be established?
    Autier P
    Ann Oncol; 2002 Jan; 13(1):57-60. PubMed ID: 11863112
    [No Abstract]   [Full Text] [Related]  

  • 32. Diagnostic yield of a one sample immunochemical test at different cut-off values in an organised screening programme for colorectal cancer.
    Hamza S; Dancourt V; Lejeune C; Bidan JM; Lepage C; Faivre J
    Eur J Cancer; 2013 Aug; 49(12):2727-33. PubMed ID: 23601670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test.
    Levi Z; Hazazi R; Rozen P; Vilkin A; Waked A; Niv Y
    Aliment Pharmacol Ther; 2006 May; 23(9):1359-64. PubMed ID: 16629942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
    Musil D; Tillich J
    Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Return to bowel screening after a false-positive faecal immunochemical test in BowelScreen (the National Bowel Screening Programme in Ireland).
    Ch'ng BX; Mooney T; O'Donoghue D; Fitzpatrick P
    J Med Screen; 2019 Dec; 26(4):186-190. PubMed ID: 31345130
    [No Abstract]   [Full Text] [Related]  

  • 36. The impact of immunochemical faecal occult blood testing on colorectal cancer incidence.
    Ventura L; Mantellini P; Grazzini G; Castiglione G; Buzzoni C; Rubeca T; Sacchettini C; Paci E; Zappa M
    Dig Liver Dis; 2014 Jan; 46(1):82-6. PubMed ID: 24011791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
    Tinmouth J; Lansdorp-Vogelaar I; Allison JE
    Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for colorectal cancer by faecal occult blood test: comparison of immunochemical tests.
    Castiglione G; Zappa M; Grazzini G; Rubeca T; Turco P; Sani C; Ciatto S
    J Med Screen; 2000; 7(1):35-7. PubMed ID: 10807145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom.
    UK Colorectal Cancer Screening Pilot Group
    BMJ; 2004 Jul; 329(7458):133. PubMed ID: 15237087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.